

AD \_\_\_\_\_

GRANT NO: DAMD17-94-J-4323

TITLE: Tumor Specific Immunotherapy of Mammary Cancer

PRINCIPAL INVESTIGATOR: Dr. Suzanne Ostrand-Rosenberg

CONTRACTING ORGANIZATION: University of Maryland Baltimore County  
Baltimore, MD 21228-5398

REPORT DATE: September 13, 1995

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel  
Command  
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release;  
distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

DTIC QUALITY INSPECTED 1

# REPORT DOCUMENTATION PAGE

Form Approved  
DMS No. 2704-0158

Public report and/or order for the collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (2704-0158), Washington, DC 20503.

1. AGENCY USE ONLY (Leave blank) 2. REPORT DATE 3. REPORT TYPE AND DATES COVERED

September 13, 1995 Annual 17 Aug 94 - 16 Aug 95

4. TITLE AND SUBTITLE

Tumor Specific Immunotherapy of Mammary Cancer

5. FUNDING NUMBERS

DAMD17-94-J-4323

6. AUTHOR(S)

Dr. Suzanne Ostrand-Rosenberg

7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)

University of Maryland Baltimore County  
Baltimore, Maryland 21228-5398

8. PERFORMING ORGANIZATION  
REPORT NUMBER

9. SPONSORING, MONITORING AGENCY NAME(S) AND ADDRESS(ES)

U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

10. SPONSORING, MONITORING  
AGENCY REPORT NUMBER

11. SUPPLEMENTARY NOTES

19960208 146

12a. DISTRIBUTION/AVAILABILITY STATEMENT

Approved for public release; distribution unlimited

12b. DISTRIBUTION CODE

13. ABSTRACT  
For many patients with mammary cancer the primary tumor can be successfully treated by surgical removal, however the long-term prognosis is not favorable because of the high frequency of metastatic disease which is not treatable by current approaches. Our goal is to develop vaccination strategies to minimize metastatic disease. We postulate that an improvement in the generation of mammary carcinoma-specific CD4<sup>+</sup> T helper lymphocytes will facilitate development of CD8-mediated tumor immunity. To enhance the activation of CD4<sup>+</sup> T helper cells, autologous mouse mammary tumor cells are being transfected with syngeneic MHC class II genes plus a variety of costimulatory and adhesion molecules, including B7-1, B7-2, 4-1BB ligand, and ICAM-1. The genetically modified tumor cells should be able to directly present mammary tumor peptides to CD4<sup>+</sup> T cells, thereby facilitating their activation. Transfectants are being tested for their tumorigenicity, for their ability to protect tumor-free mice from subsequent exposure to mammary tumor cells, and for their ability to vaccinate against spontaneous metastatic disease in a post-surgical situation.

14. SUBJECT TERMS

mammary cancer, tumor immunology, T helper lymphocytes, MHC  
breast cancer

15. NUMBER OF PAGES

12

16. PRICE CODE

17. SECURITY CLASSIFICATION  
OF REPORT

Unclassified

18. SECURITY CLASSIFICATION  
OF THIS PAGE

Unclassified

19. SECURITY CLASSIFICATION  
OF ABSTRACT

Unclassified

20. LIMITATION OF ABSTRACT

Unlimited

## FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the US Army.

NA Where copyrighted material is quoted, permission has been obtained to use such material.

NA Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

SOR ✓ Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

SOR ✓ In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Resources, National Research Council (NIH Publication No. 86-23, Revised 1985).

NA For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

SOR ✓ In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

SOR ✓ In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

~~SOR~~ NA In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

PI - Signature Date 9.11.95.

## TABLE OF CONTENTS

(1) Front Cover	i
(2) SF 298	ii
(3) Foreword	iii
(4) Table of Contents	iv
(5) Introduction	1
(6) Body	2
(7) Conclusions	5
(8) References	5
(9) Appendix	NA

## **(5) INTRODUCTION**

For many patients with mammary cancer the primary tumor can be successfully treated by surgical removal, however the long-term prognosis is not favorable because of the high frequency of metastatic disease which is not treatable by current approaches. We are using tumor-specific immunotherapy to curtail the incidence of metastatic breast cancer. Some of the most efficient anti-tumor mediators are tumor-specific CD8<sup>+</sup> T lymphocytes. In most cases, for optimal activity CD8<sup>+</sup> T cells require "help" from antigen-specific CD4<sup>+</sup> T lymphocytes (1). Recent studies indicate that the inability of the tumor-bearing host to reject tumors may be due to a lack of adequate tumor-specific T<sub>h</sub> lymphocytes (2-5). We have therefore hypothesized that tumor-specific T<sub>h</sub> activity can be significantly improved by generating tumor cells that contain all of the necessary antigen presentation, and accessory and costimulatory molecules such that they are competent for tumor peptide presentation to CD4<sup>+</sup> T cells, and thereby facilitate T<sub>h</sub> cell activation (reviewed in reference #6). Such genetically engineered tumor cells could be used as vaccines to prevent development of metastatic breast cancer, and thereby enhance a host's tumor-specific immune response.

Because of the initial complexity of the genes being tested, we are using 3 different mouse BALB/c derived mammary tumor models for our studies. The highly malignant 4T07 and 4T1 lines were derived from the spontaneous 410.4 mammary carcinoma and are weakly immunogenic and non-immunogenic, respectively, and the 4T1 subline is spontaneously metastatic while the 4T07 subline is only metastatic if inoculated intravenously (7). Both lines have been adapted for growth in tissue culture (8). The Ts/A-pc mouse mammary carcinoma is also highly malignant and spontaneously metastatic (9).

Our strategy is to genetically modify tumor cells so that they can directly present mammary carcinoma tumor peptides to CD4<sup>+</sup> T helper cells, thereby bypassing the requirement for professional antigen presenting cells and making more efficient the presentation of tumor peptides to T helper lymphocytes (reviewed in reference #6). Accordingly, in the *first specific aim* we are using DNA-mediated gene transfer techniques (2) to generate mammary tumor cell transfectants expressing many of the molecules constitutively expressed by professional antigen presenting cells (APC). These molecules include the peptide binding structures or MHC class II molecules, as well as several costimulatory molecules which have been shown to deliver the requisite second signal for T cell activation. The costimulatory molecules to be used include: B7-1 (reviewed in references 10,11), B7-2 (12-15) and 4-1BB ligand (16-19). 4-1BB ligand is a very recently described

costimulatory molecule that is expressed by professional APC such as macrophages and B lymphocytes. Binding of 4-1BB ligand to its counterreceptor 4-1BB on CD4<sup>+</sup> and CD8<sup>+</sup> T cells transmits a potent costimulatory signal to the T cells resulting in T cell activation. Since 4-1BB ligand appears to function independently or synergistically with other costimulatory molecules (16) it appears to be an excellent candidate for coexpression with B7 genes for enhancing tumor-specific immunity. Mammary tumor cells expressing the cytokines IL-1 (20) and IL-12 (21,22), potent inducers of T<sub>h2</sub> and T<sub>h1</sub> lymphocytes, respectively, are also being generated. In addition the adhesion molecule ICAM-1 (23) which is known to facilitate antigen presentation between APC and T cells is being transfected into the mammary tumor lines.

In the *second specific aim* we are determining the tumorigenicity of the transfectants, and their ability to protect the syngeneic host against subsequent challenges of wild type tumor. We will also determine the ability of the transfectants to "rescue" mice carrying established wild type mammary tumors, and identify the helper and effector lymphocytes functional in mammary tumor rejection. In the *third specific aim* we are determining if metastatic mammary cancer can be reduced or prevented by immunization or concomitant treatment with the tumor cell transfectants. This novel tumor-specific immunotherapy approach should significantly improve the host's immune response to autologous breast tumor, and may provide several potential strategies for immune intervention in metastatic mammary cancer.

## 6. BODY

The first year of the grant period has been spent establishing the mammary tumor system, testing the malignant potential of two of the tumor cell lines, and generating tumor cell transfectants. In addition, studies on other tumor systems on-going in the lab have yielded information that has helped us to fine-tune our proposed experiments.

Transfection of Balb/c derived 4T1 and 4T07 tumor cells with syngeneic MHC class II genes, B7 costimulatory genes, and/or 4-1BBL gene. The first specific aim is to generate mammary carcinoma transfectants expressing syngeneic MHC class II plus costimulatory and/or adhesion molecules. Since the 4T1, 4T07 and Ts/A mammary lines are derived from BALB/c mice, we are transfecting them with syngeneic (ie H-2<sup>d</sup>) haplotype MHC class II genes. Mammalian expression vectors carrying the Aa<sup>d</sup> and Ab<sup>d</sup> MHC class II genes (24), B7-1 (25) and B7-2 (26) genes, and 4-1BBL gene (18) have been obtained, purified, and characterized as previously described for other plasmids (2).

Unfortunately, restriction mapping of the *Ab<sup>d</sup>* gene that was initially obtained from a colleague indicated that the purported *Ab<sup>d</sup>* gene was not the correct gene. As a result we had to obtain a bonifide *Ab<sup>d</sup>* gene from another colleague. Restriction analysis of the secondarily obtained *Ab<sup>d</sup>* gene and the *Aa<sup>d</sup>* gene revealed the appropriate 0.75 kb inserts in the 3.0 kb pCEXV-3 (24). Digests with Bgl1, Xho1, Pst1, or EcoR1 plus Hinc2 also gave the predicted sized bands for the *Aa<sup>d</sup>* and *Ab<sup>d</sup>* plasmids.

Since we propose to generate transfectants expressing multiple genes, it is necessary use several drug selection markers. We have therefore obtained the pSV2neo (encoding G418 resistance; 2), pSV2hph (encoding hygromycin resistance; 27), and pMT3 (dihydrofolate reductase gene [dhfr] encoding methotrexate resistance; 28) plasmids for cotransfection with the MHC class II and other plasmids. Doses of G418, hygromycin and methotrexate for selection of 4T1 and 4T07 transfectants have been optimized as previously described for G418 resistance (2), and are shown in table 1.

**Table 1:** Optimized drug selection conditions for mammary carcinoma transfectants.

Cell Line	Drug for Selection		
	Hygromycin ( $\mu$ g/ml)	G418 ( $\mu$ g/ml)	dhfr ( $\mu$ M)
4T1	400-800	800	0.5
4T07	800	400-800	0.5

Transfection conditions for the 4T1 and 4T07 mammary tumor cell lines have been optimized by titering the amount of Lipofection (Gibco/BRL) tolerated by the cells during a 24 hour period under the standard transfection conditions (2). Both cell lines titrated at 40  $\mu$ g Lipofectin/3 ml/10<sup>6</sup> cells/24 hours. Quantities of DNA for transfection were also optimized, and are 2-10 $\mu$ g *Aa<sup>d</sup>* plasmid, 2-10  $\mu$ g *Ab<sup>d</sup>* plasmid and 1  $\mu$ g drug selection plasmid (pSV2neo, pSV2hph, or pMT3) for 20-24 hours. We are currently generating the transfectants (4T07/*A<sup>d</sup>*, 4T1/*A<sup>d</sup>*, 4T07/B7-1, 4T1/B7-2, 4T07/4-1BBL, 4T1/4-1BBL, etc.) which will be tested by indirect immunofluorescence (2) for expression of the transfected genes.

Monoclonal antibodies for testing class II expression by the transfectants have been obtained, purified and tested as previously described for other monoclonal antibodies (2) on known *A<sup>d</sup>* positive cells (MKD6 and 34-5-3 mAbs;

29,30). Monoclonal antibodies for testing B7-1 (1G10 mAb, 25) and B7-2 (31) costimulatory molecule expression have been obtained from Dr. N. Nabavi, U. of S. Carolina. A fusion protein consisting of the 4-1BB protein fused to alkaline phosphatase (16) has been obtained from Dr. Byoung Kwon for testing expression of 4-1BB ligand. With the exception of the 4-1BB fusion protein, all of the mAbs have been extensively tested by indirect immunofluorescence for specificity on MHC class II I-A<sup>d</sup> positive and negative control cells. We have also confirmed by indirect immunofluorescence that the 4T1 and 4T07 cell lines do not constitutively express I-A<sup>d</sup> class II molecules.

Table 2: Lack of effect of expression of HSA on sarcoma growth.

Immunotherapeutic Cells	Mean Survival Time ± SE (days)
None	29 ± 3.6
Sal/A <sup>k</sup> /HSA	30 ± 2.8

The heat stable antigen (HSA) gene therapy experiments of the original proposal have been deleted, because HSA was shown in other tumor systems to not be an effective immunotherapeutic agent. We have decided not to use the heat stable antigen (HSA) gene because results in our lab with a sarcoma tumor have failed to demonstrate an enhancement of tumor-specific immunity following expression of HSA. As shown in Table 2, mice challenged s.c. with the wild type Sal/N sarcoma and then treated with HSA transfected class II positive sarcoma cells (Sal/A<sup>k</sup>/HSA tumor) do not show significantly improved survival compared to mice not treated with Sal/A<sup>k</sup>/HSA cells. The HSA gene therefore does not appear to significantly improve immunity to established tumor, as compared to the B7-1 costimulatory gene which in a similar experimental protocol mediates rejection of up to 50% of established sarcoma tumors (27). Instead of the HSA gene, we will therefore use the 4-1BB ligand gene (18). As discussed in the *Introduction* of this report, 4-1BBL is the costimulatory molecule that interacts with the recently described counterreceptor 4-1BB. Because of the potent costimulatory activity ascribed to 4-1BBL it appears to be an excellent candidate gene for facilitating the activation of tumor-specific T cells. We have therefore added the 4-1BBL gene to our panel of genes for transfection, and will introduce it into the various mammary carcinoma tumors.

4T07 and 4T1 mammary carcinoma lines are being tested for their tumorigenicity, immunogenicity, and metastatic potential. The 4T07 and 4T1

mammary tumor lines have been obtained, and are being titered for their ability to form solid (subcutaneous) tumors, and to metastasize in syngeneic BALB/c mice, using techniques previously described (2, 27). Solid tumor formation is being monitored by s.c. inoculation of graded doses of tumor cells ( $10^5$ ,  $5 \times 10^5$ , and  $10^6$ ) into the flank. Developing tumors are measured 2-3 times per week, and mice are euthanized when the tumors reach approximately 2-3 cm in diameter. At this size tumor the mice are not in obvious distress, and hence the tumor incidence studies are being conducted with minimal pain and distress to the test animals. Metastasis formation is being assessed by intravenous inoculation of graded doses of tumor cells ( $10^4$ ,  $5 \times 10^4$ , and  $10^5$ ) into the tail vein. Mice are sacrificed 3 weeks post inoculation, the lungs perfused with India ink, and the number of lung metastases counted. The liver and abdominal region of the sacrificed mice are also checked for metastases. In the future we plan to develop an assay for spontaneous metastases by surgically removing primary solid (s.c.) tumors and monitoring the mice post-surgically for spontaneous metastases in the lungs, liver, and draining lymph nodes.

## **7. CONCLUSIONS**

This initial grant year has been spent establishing the mammary carcinoma tumor system, characterizing and generating the necessary plasmids and genes for transfection, and optimizing the transfection conditions for the mammary carcinoma cells. Since most of the reagents are now prepared and the tumors have been characterized, we are in a position to initiate the proposed immunotherapy experiments.

## **8. REFERENCES**

1. Kern, D., J. Klarnet, M. Jensen, and P. Greenberg, 1986. Requirement for recognition of class II molecules and processed tumor antigen for optimal generation of syngeneic tumor-specific class I-restricted CTL. *J. Immunol.* **136**: 4303.
2. Ostrand-Rosenberg, S., A. Thakur, and V. Clements 1990. Rejection of mouse sarcoma cells after transfection of MHC class II genes. *J. Immunol.* **144**:4068.
3. Tepper, R., P. Pattengale, and P. Leder, 1989. Murine IL-4 displays potent anti-tumor activity in vivo. *Cell* **57**:503.

4. Fearon, E., D. Pardoll, T. Itaya, P. Golumbek, H. Levitsky, J. Simons, H. Karasuyama, B. Vogelstein, and P. Frost, 1990. IL-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. *Cell* 60:397.
5. Schultz, K., J. Klarnet, R. Gieni, K. Hayglass, and P. Greenberg, 1990. The role of B cells for in vivo T cell responses to a friend virus-induced leukemia. *Science* 249:921.
6. Ostrand-Rosenberg, S., 1994. Enhancing tumor immunity: The tumor cell as an antigen presenting cell. *Curr. Opinion Immunol.* 6:722.
7. Heppner, G. and B. Miller, 1983. Tumor heterogeneity: biological implications and therapeutic consequences. *Canc. Metastasis Rev.* 2:5.
8. Aslakson, C. and F. Miller, 1992. Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. *Canc. Res.* 52:1399.
9. Cavallo, F., F. Di Pierro, M. Giovarelli, A. Gulino, A. Vacca, A. Stoppacciaro, M. Forni, A. Modesti, and G. Forni, 1993. Protective and curative potential of vaccination with IL-2 gene transfected cells from a spontaneous mouse mammary adenocarcinoma. *Canc. Res.* 53:6067.
10. June, C., J. bluestone, L. Nadler, and C. Thompson, 1994. The B7 and CD28 receptor families. *Immunol. Today* 15:321.
11. Thompson, C., 1995. Distinct roles for the costimulatory ligands B7-1 and B7-2 in T helper cell differentiation? *Cell* 81:979.
12. Azuma, M., D. Ito, H. Yagita, K. Okumura, J. Phillips, L. Lanier, and C. Somoza, 1993. B70 antigen is a second ligand for CTLA-4 and CD28. *Nature* 366:76.
13. Freeman, G., F. Borriello, R. Hodes, H. Reiser, K. Hathcock, G. Laszlo, A. McKnight, J. Kim, L. Du, D. Lombard, G. Gray, L. Nadler, and A. Sharpe. Uncovering of functional alternative CTLA-4 counter-receptor in B7-deficient mice. *Science* 262:907.
14. Hathcock, K., G. Laszlo, H. Dickler, J. Bradshaw, P. Linsley, and R. Hodes,

1993. Identification of an alternative CTLA-4 ligand costimulatory for T cell activation. *Science* **262:905**.
15. Razi-Wolf, Z., F. Galvin, G. Gray, and H. Reiser, 1993. Evidence for an additional ligand, distinct from B7, for the CTLA-4 receptor. *Proc. Natl. Acad. Sci. USA* **90:11182**.
  16. De Benedette, M., N. Chu, K. Pollock, J. Hurtado, W. Wade, B. Kwon, and T. Watts, 1995. Role of 4-1BB ligand in costimulation of T lymphocyte growth and its upregulation of M12 B lymphomas by cAMP. *J. Exp. Med.*, *in press*.
  17. Pollock, K., Y. Kim, J. Hurtado, Z. Shou, K. Kim, and B. Kwon, 1994. 4-1BB T cell antigen binds to mature B cells and macrophages and costimulates anti- $\mu$  primed splenic B cells. *Eur. J. Immunol.* **24:367**.
  18. Goodwin, R., W. Din, T. Davis-Smith, D. Anderson, S. Gimpel, T. Sato, C. Maliszewski, C. Branna, N. Copeland, N. Jenkins, T. Farrah, R. Armitage, W. Fanslow, and C. Smith, 1993. Molecular cloning of a ligand for the inducible T cell gene 4-1BB: a member of an emerging family of cytokines with homology to tumor necrosis factor. *Eur. J. Immunol.* **23:2641**.
  19. Pollock, K., Y. Kim, Z. Zhou, J. Hurtado, K. Kim, R. Pickard, and B. Kwon, 1993. Inducible T cell antigen 4-1BB. *J. Immunol.* **150:771**.
  20. Gruber, M., D. Webb, and T. Gerrard, 1992. Stimulation of human monocytes via DC45, CD44, and LFA-3 triggers MCSF production: synergism with lipopolysaccharide and IL-1 $\beta$ . *J. Immunol.* **148:1113**.
  21. Manetti, R., P. Parronchi, M. Guidizi, M. Piccinni, E. Maggi, G. Trinchieri, and S. Romagnani, 1993. Natural killer cell stimulatory factor (IL-12) induces T helper type 1 specific immune response and inhibits the development of IL-4 producing T<sub>H</sub> cells. *J. Exp. Med.* **177:1199**.
  22. Schoenhaut, D., A. Chua, A. Wolitzky, P. Quinn, C. Dwyer, W. McComas, P. Familletti, M. Gately, and U. Gubler, 1992. Cloning and expression of murine IL-12. *J. Immunol.* **148:3433**.
  23. Siu, G., S. Hedrick, and A. Brian, 1989. Isolation of the murine intercellular adhesion molecule 1 (ICAM-1) gene. *J. Immunol.* **143:3813**.

24. Miller, J. and R. Germain, 1986. Efficient cell surface expression of class II MHC molecules in the absence of associated invariant chain. *J. Exp. Med.* **164:1478.**
25. Nabavi, N., G. Freeman, A. Gault, D. Godfrey, L. Nadler, and L. Glimcher, 1992. Signalling through the MHC class II cytoplasmic domain is required for antigen presentation and induces B7 expression. *Nature* **360:266.**
26. Chen, C., A. Gault, L. Shen, and N. Nabavi, 1994. Molecular cloning and expression of early T cell costimulatory molecule-1 and its characterization as B7-2 molecule. *J. Immunol.* **152:4929.**
27. Baskar, S., L. Glimcher, N. Nabavi, R. Jones, and S. Ostrand-Rosenberg, 1995. Major histocompatibility complex class II<sup>+</sup>B7-1<sup>+</sup> tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice. *J. Exp. Med.* **181:619.**
28. Bonthron, D., R. Handin, R. Kaufman, L. Wasley, E. Orr, L. Mitsock, B. Ewenstein, J. Loscalzo, D. Ginsburg, and S. Orkin, 1986. Structure of pre-pro-von Willebrand factor and its expression in heterologous cells. *Nature* **324:270.**
29. Kappler, J., B. Skidmore, J. White, and P. Marrack, 1981. Antigen-inducible, H-2 restricted, IL-2 producing T cell hybridomas. *J. Exp. Med.* **153:1198.**
30. Ozato, K., N. Mayer, and D. Sachs, 1982. Monoclonal antibodies to mouse major histocompatibility complex antigens. *Transplantation* **34:113.**
31. Chen, C., D. Faherty, A. Gault, S. Connaughton, G. Powers, D. Godfrey, and N. Nabavi, 1994. Monoclonal antibody 2D10 recognizes a novel T cell costimulatory molecule on activated murine B lymphocytes. *J. Immunol.* **152:2105.**

9. **APPENDIX** None.